ESMO: Seagen's Padcev pulls its weight in combo with Merck's Keytruda

The combination of Merck’s Keytruda and Seagen and Astella’s Padcev has made noise as a possible option for untreated cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer.